ABEO Key Statistics, Chart & Performance
The current stock price of ABEO is 5.19 USD. In the past month the price increased by 2.17%. In the past year, price decreased by -0.57%.
ABEO Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ABEO. When comparing the yearly performance of all stocks, ABEO is a bad performer in the overall market: 69.77% of all stocks are doing better.
ABEO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ABEO. While ABEO seems to be doing ok healthwise, there are quite some concerns on its profitability.
ABEO Financial Highlights
Over the last trailing twelve months ABEO reported a non-GAAP Earnings per Share(EPS) of -1.01. The EPS increased by 57.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 20587.5% | ||
| ROA | 35.63% | ||
| ROE | 48.09% | ||
| Debt/Equity | 0.06 |
ABEO Forecast & Estimates
12 analysts have analysed ABEO and the average price target is 21.06 USD. This implies a price increase of 305.7% is expected in the next year compared to the current price of 5.19.
For the next year, analysts expect an EPS growth of 172.22% and a revenue growth 6533.33% for ABEO
ABEO Ownership
ABEO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.48 | 392.16B | ||
| AMGN | AMGEN INC | 15.04 | 177.14B | ||
| GILD | GILEAD SCIENCES INC | 15.15 | 153.93B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.89 | 114.05B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.75 | 79.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 719.33 | 48.47B | ||
| INSM | INSMED INC | N/A | 34.86B | ||
| NTRA | NATERA INC | N/A | 33.01B | ||
| BIIB | BIOGEN INC | 10.11 | 24.84B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.43B | ||
| INCY | INCYTE CORP | 16.5 | 20.80B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.03 | 20.48B |
Related stock screener links
About ABEO
Company Profile
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. The company is headquartered in Cleveland, Ohio and currently employs 136 full-time employees. The firm's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).
Company Info
ABEONA THERAPEUTICS INC
6555 Carnegie Ave, 4th Floor
CLEVELAND OHIO 75219 US
CEO: Michael Amoroso
Employees: 136
Phone: 16468134701
ABEONA THERAPEUTICS INC / ABEO FAQ
Can you describe the business of ABEONA THERAPEUTICS INC?
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. The company is headquartered in Cleveland, Ohio and currently employs 136 full-time employees. The firm's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).
Can you provide the latest stock price for ABEONA THERAPEUTICS INC?
The current stock price of ABEO is 5.19 USD. The price increased by 1.96% in the last trading session.
Does ABEONA THERAPEUTICS INC pay dividends?
ABEO does not pay a dividend.
What is the ChartMill rating of ABEONA THERAPEUTICS INC stock?
ABEO has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Should I buy ABEO stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ABEO.
Can you provide the market cap for ABEONA THERAPEUTICS INC?
ABEONA THERAPEUTICS INC (ABEO) has a market capitalization of 281.25M USD. This makes ABEO a Micro Cap stock.
What is the outstanding short interest for ABEONA THERAPEUTICS INC?
The outstanding short interest for ABEONA THERAPEUTICS INC (ABEO) is 28.81% of its float.